I The homogeneity of /$-adrenoceptors in femoral, superior mesenteric and renal vascular beds was investigated by the use of the regional perfusion technique in dogs. 2 Isoprenaline and salbutamol produced dose-related increases in femoral and superior mesenteric blood flow. The dose-response curves for the two agonists were parallel, but salbutamol was approximately 1/15 as potent as isoprenaline on a weight basis. 3 Isoprenaline and salbutamol increased renal blood flow in a dose-related manner. However, salbutamol was approximately 1/240 as potent as isoprenaline on a weight basis, and the slope of the dose-response curve for salbutamol was less steep than that for isoprenaline. 4 The dose-response curves to isoprenaline for increase in femoral and superior mesenteric blood flow were shifted to the right by intravenous pindolol but not by intravenous or intra-arterial practolol. 5 The dose-response curves to isoprenaline for increase in renal bood flow were shifted to the right more markedly by intravenous pindolol than by intravenous or intra-arterial practolol.
Introduction Methods
Lands and his co-workers (Lands, Arnold, McAuliff, Luduena & Brown, 1967a; Lands, Luduena & Buzzo, 1967b) proposed that P-adrenoceptors could be divided into a f,-group in cardiac muscle and a 02-group in bronchial and vascular smooth muscle. Recent work suggests that not only do /Jadrenoceptors in bronchial and vascular smooth muscle differ from those in cardiac muscle but that /iadrenoceptors in the former two sites are also not homogeneous (Bristow, Sherrod & Green, 1970; Wasserman & Levy, 1974; Wardell, Colella, Shetzline & Fowler, 1974) . Little is known about the homogeneity of P-adrenoceptors in the vasculature.
The present experiments were designed to test this point. For this purpose the femoral, superior mesenteric and renal vascular beds were perfused by the use of the regional perfusion technique (Hashimoto & Kumakura, 1965) in dogs anaesthetized with pentobarbitone.
Adult mongrel dogs of either sex, weighing 15-18 kg, were anaesthetized with pentobarbitone sodium initially at a dose of 30 mg/kg (i.v.) and received heparin sodium at a dose of 500 units/kg (i.v.) .
Subsequently pentobarbitone sodium was infused intravenously at a rate of 4 mg kg-' h-' and heparin sodium at a rate of 100 units kg-' h-' by the use of an infusion pump (Harvard Apparatus, Model 600). 
Results
Effects of isoprenaline and salbutamol on femoral, superior mesenteric and renal blood flow Femoral and superior mesenteric blood flow at a perfusion pressure of 100 mmHg was 46 + 7 ml/min (n 15) and 108 + 7 ml/min (n= 15), respectively. Intra-arterial injections of isoprenaline (0.01-1 ,utg) and of salbutamol (0.1-0 -Ogg) increased blood flow through both arteries in a dose-related manner. Doseresponse curves to isoprenaline and to salbutamol for peak increases in blood flow were parallel in both circulations (Figure la,b) . When compared on the basis of doses (ED, 20 ml/min) increasing blood flow by 20 ml/min, the potency of salbutamol was almost 1/15 that of isoprenaline on a weight basis in the two vascular beds.
In all experiments on renal circulation the animals renal blood flow. Figure Ic shows dose-response curves to the two agonists for peak increase in blood flow. As seen in this figure, the slope of the doseresponse curve for salbutamol was less steep than that for isoprenaline. When compared on the basis of doses (ED, 1O ml/min) increasing the renal blood flow by 1O ml/min, the potency of salbutamol was approximately 1/240 that of isoprenaline on a weight basis. These doses, apart from the highest doses used of isoprenaline and salbutamol injected intra-arterially, had almost no systemic effect.
Differential modification by pindolol and practolol of the effect of isoprenaline on femoral and superior mesenteric blood flow The dose-response curves to isoprenaline for increases in femoral and superior mesenteric blood flow were shifted almost in a parallel fashion to the right by intravenous injections of pindolol (3 jg/kg) ( Figure  2a, b) . In contrast, the dose-response curves to isoprenaline for increase in femoral blood flow were not altered significantly by intravenous injections of practolol (0.3 and 3 mg/kg) ( Figure 3a) . The doseresponse curves to isoprenaline for increase in superior mesenteric blood flow were also not modified by intraarterial infusions of practolol (100 and 300 jg/min) ( Figure 3b respectively ( Table 1 ), indicating that the doses of practolol produced shifts of 0.3 and 0.7 log units of the dose-response curves for isoprenaline to the right. Essentially similar antagonism of renal blood flow responses to isoprenaline (0.03-0.3 tg i.a.) was obtained with intra-arterial infusions of practolol (10-300 ig/min) (Table 1 ). Figure 5 illustrates typical experiments. The blocking effect of practolol was reversible; the blood flow response to isoprenaline recovered to a control level 5-20 min after interruption of infusion of practolol. Dose-response curves for isoprenaline before and during intra-arterial infusions of practolol are shown in Figure 6 . In this figure, it should be noted that the response to isoprenaline at a dose as small as 0.03,g was not completely inhibited by practolol. t Log ED, 10 ml/min ratio was calculated from the following equation: log ED, 10 ml/min ratio=log ED, 10 ml/min for isoprenaline in the presence of a P-adrenoceptor antagonist minus log ED, 10 ml/min for isoprenaline in the absence of a P-adrenoceptor antagonist.
* Significantly different from control values (P < 0.05). On the other hand, intravenous injections of pindolol (3 and 10jg/kg) shifted the dose-response curves for isoprenaline (0.03-10jIg i.a.) and for salbutamol (0.1-100 jLg i.a.) to the right (Figure 7a,b) . Log ratios of ED, 10 m/min for isoprenaline after 3 and 10 g/kg i.v. of pindolol to ED, 1O ml/min in control were 0.9 and 1.7, respectively (Table 1) . These values were greater than the log ED, 10 nvmin ratios obtained with 0.3 and 3 mg/kg of intravenous practolol. In the present experiments the dose-response curves to isoprenaline and salbutamol for increase in femoral or superior mesenteric blood flow were almost parallel. In both vascular beds salbutamol was approximately 1/15 as potent as isoprenaline on a weight basis. The present results were thus consistent with those obtained by Cullum, Farmer, Jack & Levy (1969) and by Wasserman & Levy (1974) who found that salbutamol was 1/10 to 1/20 as potent as isoprenaline in increasing blood flow through or in decreasing perfusion pressure of the dog hind limb. Salbutamol is more selective on bronchial and vascular /Badrenoceptors than on cardiac ,6-adrenoceptors (Cullum et al., 1969; Daly, Farmer & Levy, 1971; Wasserman & Levy, 1974) and belongs to selective stimulants of 0l2-adrenoceptors classified by Lands et al. (1967a,b) . In the present experiments the position of the dose-response curve to isoprenaline for increase in femoral blood flow was not significantly altered by intravenous injection of practolol and the doseresponse curve to isoprenaline for increase in superior mesenteric blood flow was also not significantly modified by intra-arterial infusion of practolol. In contrast, the two dose-curves for isoprenaline were effectively shifted to the right by pindolol. Practolol antagonizes the positive chronotropic and inotropic effects but not the vasodilator action of isoprenaline (Dunlop & Shanks, 1968) , and can be classified as a selective , -adrenoceptor antagonist. Unlike practolol, pindolol blocks non-selectively P-adrenoceptors in cardiac muscle and in bronchial and vascular smooth muscle (Giudicelli, Schmitt & Boissier, 1969; Yabuuchi & Kinoshita, 1974 (1967a,b) . In the present experiments in which the animals were treated initially with phenoxybenzamine, intraarterial injection of isoprenaline produced an increase in renal blood flow. The results are in accord with those of McNay & Goldberg (1966) . Salbutamol also increased the renal blood flow. However, the potency of salbutamol in increasing renal blood flow was approximately 1/240 that of isoprenaline on a weight basis. Thus, the difference in potency between isoprenaline and salbutamol as vasodilators in the renal vascular bed was much greater than that between the two compounds in the femoral or superior mesenteric vascular beds. Furthermore, the doseresponse curve to salbutamol for increase in renal blood flow was less steep than that to isoprenaline. These observations suggest that,-adrenoceptors in the renal vascular bed may be different from those in the femoral and superior mesenteric vascular beds. The dose-response curve to isoprenaline for increase in renal blood flow was shifted almost in a parallel fashion to the right by intravenous or intra-arterial practolol in doses which did not significantly change the dose-response curves to isoprenaline for increases in femoral and superior mesenteric blood flow. However, the renal blood flow response to isoprenaline at a dose as small as 0.03 1±g was not completely abolished even by intra-arterial infusion at a maximal rate of 300 ,ug/min of practolol used in the present experiments. A 10-fold increase in intravenous or intra-arterial doses of practolol produced a shift of approximately 0.4 log units to the right in the doseresponse curves to isoprenaline for increase in renal blood flow, whereas only a 3-fold increase in intravenous doses of pindolol induced a shift of 0.8 log units. This difference in displacement of the doseresponse curves for isoprenaline by pindolol and practolol may be explained on the basis of the difference in P-adrenoceptor blocking properties of pindolol and practolol, mentioned in the preceding paragraph. Furthermore the increase in renal blood flow induced by salbutamol was not antagonized by practolol but was by pindolol. The failure of practolol to modify the effect of salbutamol may be attributed to the weaker stimulant property of salbutamol on filadrenoceptors than on P2-adrenoceptors. From these results, it can be concluded that P-adrenoceptors of both the /31-type and 832-type proposed by Lands et al. (1967a,b) 
